Supplemental Figure Legends Supplemental Fig. 1. The reduced 5-FU IC50 levels after combined with embelin treatment in gastric cancer cell lines. The results are presented as the mean of three independent experiments, and the bars indicate the SD. Oneway ANOVA was used to analyze the data. *P<0.05 and **P<0.001, compared with each agent alone. Supplemental Fig. 2. The changed cell cycle phase distributions after treatment with embelin of gastric cancer KATO-III and NCI-N87 cells. The cells were treated with embelin at 10 μM, 20μM, or 40 μM, for 72 h and subjected to flow cytometry. The values in the insert represent mean values of three independent experiments. Supplemental Fig. 3. Flow cytometry analysis of gastric cancer AGS cell apoptosis. The cells were treated with different concentrations of embelin for 24 h. Dot plots display the apoptosis of AGS cells treated with embelin at 10 μM, 20μM, and 40 μM. The cells were stained with Annexin V-FITC and PI. The values in the insert represent mean values of three independent experiments. Supplemental Fig. 4. Differential protein expression and phosphorylation after embelin treatment in gastric cancer cells. These three gastric cancer cell lines were treated with embelin at concentrations of IC 75 for 48 h and levels of these proteins were determined by PPA analyses. Forty-six proteins and phosphorylated proteins were shown to have >1.5-fold changes compared with the controls in AGS, 48 in KATO-III, and 45 in NCI-N87 cells. The results represent the mean number of changes of two independent experiments. Supplemental Table 1. Patients’ demographics and clinicopathological characteristics Number of patients (%) Clinicopathological characteristics (n=41) Age ≤60yr 15 (36.6) >60 26 (63.4) Gender Male 24 (58.5) Female 17 (41.5) Histologic differentiation Moderate 11 (26.8) Poor 30 (73.2) TNM stage1 I 2(4.9) II 7(17.1) III 28 (68.3) IV 4(9.7) Depth of invasion pT1 1(2.4) pT2 16(39.1) pT3 19(46.3) pT4 5(12.2) Node status pN0 3(7.3) pN1 5(12.2) pN2 29(70.7) pN3 4(9.8) 1. The tumor-node-metastasis (TNM) staging was performed according to the American Joint Committee on Cancer (AJCC). No patient had metastasis to distant organs (M0).